5-Azacytidine
(Synonyms: 5-氮杂胞苷; Azacitidine; 5-AzaC; Ladakamycin) 目录号 : GC10946
5-氮胞苷（也称为 5-AzaC）是一类胞嘧啶类似物的化合物，是一种 DNA 甲基转移酶 (DNMT) 抑制剂，对多发性骨髓瘤 (MM) 细胞（包括 MM.1S）具有强效细胞毒性, MM.1R, RPMI-8266, RPMI-LR5, RPMI-Dox40和Patient-derived MM,半数抑制浓度IC50值分别为1.5 μmol/L, 0.7 μmol/L, 1.1 μmol/L, 2.5 μmol/L , 分别为 3.2 μmol/L 和 1.5 μmol/L . 5-氮胞苷掺入细胞 DNA 和/或 RNA，随后螯合 DNMT 并在 5-氮胞苷的 C6 和半胱氨酸之间形成共价键DNMT 的硫醇盐导致细胞中 DNMT 活性的耗竭和细胞 DNA 的去甲基化 。
Cas No.:320-67-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Leukemia L1210 cells |
|
Preparation method |
The solubility of this compound in DMSO is > 12.2 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
80 μM; 0 ~ 120 mins |
|
Applications |
In leukemia L1210 cells, 5-Azacytidine showed greater inhibition on DNA synthesis instead of RNA synthesis. After a 90-min preincubation, TdR-3H incorporation was inhibited by about 74%, whilst UR-3H incorporation was inhibited by only 32%. |
| Animal experiment [2]: | |
|
Animal models |
BDF1 mice bearing lymphoid leukemia L1210 cells |
|
Dosage form |
3 mg/kg; i.p.; q.d. |
|
Applications |
In BDF1 mice bearing lymphoid leukemia L1210 cells, 5-Azacytidine increased the mean survival time. Moreover, 5-Azacytidine significantly suppressed all enzymes activity in the polyamine-biosynthetic pathway. In addition, 5-Azacytidine inhibited accumulation of polyamines in leukemic mice. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970 Nov;30(11):2760-9. [2]. Heby O, Russell DH. Depression of polyamine synthesis in L1210 leukemic mice during treatment with a potent antileukemic agent, 5-azacytidine. Cancer Res. 1973 Jan;33(1):159-65. |
|
5-Azacytidine (also known as 5-AzaC), a compound belonging to a class of cytosine analogues, is a DNA methyl transferase (DNMT) inhibitor that exerts potent cytotoxicity against multiple myeloma (MM) cells, including MM.1S, MM.1R, RPMI-8266, RPMI-LR5, RPMI-Dox40 and Patient-derived MM, with the half maximal inhibition concentration IC50 values of 1.5 μmol/L, 0.7 μmol/L, 1.1 μmol/L, 2.5 μmol/L, 3.2 μmol/L and 1.5 μmol/L respectively [1].
5-Azacytidine incorporates into cellular DNA and/or RNA, subsequently sequesters DNMT and forms a covalent bond between C6 of 5-Azacytidine and cysteine thiolate of DNMTs resulting in depletion of DNMT activity in cells and demethylation of cellular DNA [1].
References:
[1] Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007 Jun;6(6):1718-27.
5-氮胞苷（也称为 5-AzaC）是一类胞嘧啶类似物的化合物,是一种 DNA 甲基转移酶 (DNMT) 抑制剂,对多发性骨髓瘤 (MM) 细胞（包括 MM.1S）具有强效细胞毒性, MM.1R, RPMI-8266, RPMI-LR5, RPMI-Dox40和Patient-derived MM,半数抑制浓度IC50值分别为1.5 μmol/L, 0.7 μmol/L, 1.1 μmol/L, 2.5 μmol/L , 分别为 3.2 μmol/L 和 1.5 μmol/L [1].
5-氮胞苷掺入细胞 DNA 和/或 RNA,随后螯合 DNMT 并在 5-氮胞苷的 C6 和半胱氨酸之间形成共价键DNMT 的硫醇盐导致细胞中 DNMT 活性的耗竭和细胞 DNA 的去甲基化 [1]。
| Cas No. | 320-67-2 | SDF | |
| 别名 | 5-氮杂胞苷; Azacitidine; 5-AzaC; Ladakamycin | ||
| 化学名 | 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one | ||
| Canonical SMILES | C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N | ||
| 分子式 | C8H12N4O5 | 分子量 | 244.2 |
| 溶解度 | ≥ 12.21mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.095 mL | 20.475 mL | 40.95 mL |
| 5 mM | 0.819 mL | 4.095 mL | 8.19 mL |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.095 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。